Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

1.4%

1 terminated/withdrawn out of 74 trials

Success Rate

95.8%

+9.3% vs industry average

Late-Stage Pipeline

41%

30 trials in Phase 3/4

Results Transparency

2 of 23 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

28(45.9%)

Phase 2

14(23.0%)

N/A

13(21.3%)

Phase 1

4(6.6%)

Phase 3

2(3.3%)

61Total

Phase 4(28)

Phase 2(14)

N/A(13)

Phase 1(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (74)

Showing 20 of 74 trials

NCT05328778Phase 4Completed

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

Role: lead

NCT07462949Not ApplicableCompleted

A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhibiting Tracheal Intubation Stimulation Under qNOX Index Monitoring

Role: lead

NCT07265544Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Role: collaborator

NCT07303348Not ApplicableActive Not Recruiting

Multicenter Clinical Randomized Controlled Trial of Unilateral Biportal Endoscopic Spinal Surgery for Degenerative Grade 1 Spondylolisthesis Complicated With Lumbar Spinal Stenosis

Role: collaborator

NCT07145697Phase 4Recruiting

The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness

Role: lead

NCT06763666Phase 4Not Yet Recruiting

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Role: collaborator

NCT05202899Phase 4Unknown

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Role: lead

NCT05187455Phase 4Unknown

Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation